Problem

Perceptic addresses a structural problem in pharmaceutical R&D: evidence, data, decisions, and workflows are fragmented across departments and tools, so important insight is lost at handoffs. This is especially painful in drug development, where decisions can consume years of work and billions of dollars, yet the underlying systems are not designed for the complexity of modern science. The core economic pain is constrained expert bandwidth: teams must prioritize which hypotheses, assets, and data rooms they can seriously evaluate, often favoring what they have time to read over what best fits strategy.

The clearest use case is external asset scouting and due diligence. Perceptic is aimed at helping pharma teams identify licensing candidates, emerging programs, and therapeutic opportunities, then evaluate them against scientific, clinical, commercial, and strategic criteria without restarting from scratch for each opportunity. Its stated production results—compressing evaluation from a week to an hour and expanding screening from hundreds of assets per week to thousands in minutes—illustrate the value of widening the funnel while preserving expert judgment.

Product / Service

Perceptic provides an AI operating system, or shared intelligence layer, across the drug-development lifecycle. Its platform connects asset scouting, scientific evaluation, and clinical-data foundations, while sitting above a customer’s existing data, hardware, AI models, specialized software, proprietary databases, and computational tools. Scout handles external-asset discovery and ranking; PercepticOS provides the environment for testing hypotheses, comparing internal evidence with external benchmarks, and retaining organizational knowledge across projects.

The delivery model is configurable enterprise software built around modular AI workers rather than a black-box application. Scientists define the logic, constraints, heuristics, and criteria for a good result; the workers then apply that reasoning to research and decision workflows, with uncertainty quantification, traceable data sources, reasoning chains, and raw artifacts. Customers deploy the workers with their own tools and data, including through a proposed 30-day pilot, so the system compounds institutional expertise over time. The benefit is faster, broader, and more reproducible analysis without proportionally increasing headcount, while keeping humans in control of consequential scientific decisions.

Market

Perceptic competes in the emerging category of AI-first software and intelligence infrastructure for pharmaceutical and biopharmaceutical R&D, rather than in the market for AI-designed drug assets themselves. Its positioning is as a cross-lifecycle mission-control layer that connects fragmented scientific workflows, competing with the status quo of departmental systems, point tools, specialist databases, and internal processes. The public launch materials do not identify a specific direct software rival; they instead describe a category forming around an intelligence layer that follows the drug across departments. The closest competitive alternatives are therefore likely to be broader enterprise data-and-workflow platforms and specialized scientific or competitive-intelligence tools, although Perceptic says it integrates with rather than replaces much of that infrastructure.

Perceptic is commercially deployed rather than merely pre-product. It emerged from stealth in May 2026 with a $12 million seed round led by Accel alongside Air Street Capital and angels, and the company’s investors say it was already deployed at multiple top-tier or top-ten pharmaceutical companies, biotechs, and CROs, including CSL. Reported live-deployment outcomes include a 50-fold increase in clinical-data extractions, screening growth from hundreds per week to thousands in minutes, and scientific due diligence reduced from weeks to hours. No revenue figure is disclosed in the available evidence, so revenue scale cannot be assessed, but the named and unnamed deployments provide meaningful early commercial traction.